Upgrade to SI Premium - Free Trial

RBC Capital on Regeneron (REGN): 'We see potential earlier-than-expected launch of biosimilar product as incrementally negative to REGN's story'

September 23, 2024 4:40 PM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $1,282.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst said ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles